| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. [PubChem] |
| Indication |
For the treatment of gout and gouty arthritis. |
| Pharmacology |
Sulfinpyrazone's pharmacologic activity is the potentiation of the urinary excretion of uric acid. It is useful for reducing the blood urate levels in patients with chronic tophaceous gout and acute intermittent gout, and for promoting the resorption of tophi. |
| Toxicity |
Symptoms of overdose include nausea, vomiting, diarrhea, epigastric pain, ataxia, labored respiration, convulsions, coma. Possible symptoms, seen after overdosage with other pyrazolone derivatives: anemia, jaundice, and ulceration. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Half Life |
Approximately 4-6 hours |
| Protein Binding |
98-99% |
| External Links |
|
|